Harvard Bioscience Current Deferred Revenue Over Time
| HBIO Stock | USD 2.20 0.01 0.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Harvard Bioscience Performance and Harvard Bioscience Correlation. Harvard |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Harvard Bioscience and related stocks such as InfuSystems Holdings, Pro Dex, and LeMaitre Vascular Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INFU | 55 K | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 9.6 M | 9.6 M | 11.1 M | 6.7 M |
| PDEX | 1.1 M | 141 K | 141 K | 232 K | 594 K | 212 K | 19 K | 31 K | 215 K | 200 K | 150 K | 1 M | 453 K | 14 K | 13.3 K |
| LMAT | 2.6 M | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 552 K | 14 M | 17.5 M | 16.3 M | 390 K | 448.5 K | 426.1 K |
| UTMD | 1.1 M | 2.8 M | 2.8 M | (446 K) | (763 K) | (38 K) | (38 K) | (38 K) | (38 K) | (38 K) | (41 K) | (52 K) | (54 K) | 327 K | 232.6 K |
| MLSS | 86.5 K | (356.6 K) | (356.6 K) | (50 K) | (50 K) | 1 M | 1 M | 2.5 M | 521.8 K | 340.5 K | 242.6 K | 242.6 K | 242.6 K | 279 K | 495.5 K |
| POCI | 588.1 K | 6.4 K | 38 K | 26.2 K | 118.8 K | 180.1 K | 180.1 K | 857.8 K | 450.2 K | 417.1 K | 450.1 K | 905.1 K | 1.2 M | 1.2 M | 1.2 M |
| KRMD | 132.4 K | 22.5 K | 22.5 K | 22.5 K | 22.5 K | 22.5 K | 22.5 K | 3.8 K | 3.8 K | 125.3 K | 125.3 K | 90 K | 3.4 M | 1.7 M | 1.8 M |
| ANGO | 1.9 M | 3.1 M | 1.6 M | 200 K | 8.8 M | 9.4 M | 27.2 M | 32.3 M | 29.5 M | 29.5 M | (2.4 M) | 16 M | (14.8 M) | (17 M) | (16.1 M) |
| ICUI | 2.4 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.8 M | 6.7 M | 5.6 M | 12.6 M | 30.8 M | 31.6 M | 33.2 M |
| MMSI | 4.8 M | 551 K | 551 K | 292 K | 381 K | 589 K | 572 K | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 5.1 M | 5.1 M | 4.6 M | 3.9 M |
| AKYA | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 3.8 M | 4.5 M | 6.3 M | 6.7 M | 5.6 M |
Harvard Bioscience and related stocks such as InfuSystems Holdings, Pro Dex, and LeMaitre Vascular Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Harvard Bioscience | HBIO |
| Classification | Measuring and Control Equipment |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.2
Check out Harvard Bioscience Performance and Harvard Bioscience Correlation. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Harvard Bioscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.